FDA Urged To Simplify Device Labeling At Recent Gathering
This article was originally published in The Gray Sheet
FDA heard plenty of input on labeling design and use at a recent two-day public workshop, with safety and usability issues highlighted.
You may also be interested in...
US FDA has made efforts to improve health communications to cater to deficiencies in literacy; other specific topics for discussion at the meeting remain unclear.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.